The problems with continued misuse of transmucosal immediate release fentanyl products is not with the US FDA’s Risk Evaluation & Mitigation Strategy – but rather with the availability of the products at all, one of the members of FDA’s Anesthetic & Analgesic Drugs Advisory Committee that reviewed the TIRF REMS says in an email to the Pink Sheet.
“After five years of assessing the positions of the Agency, past mistakes, and the current state I am certain that there was never an indication for this drug, and that it is one of the most dangerous of all of the opioid
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?